Sign In
Buy KRYS
$301.82
+8.61 (+2.94%)
At Close: Jun 03, 2026
Krystal Biotech to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
07:00am, Thursday, 07'th Sep 2023
PITTSBURGH, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and commercializ
Krystal (KRYS) Up 5% on Sale of FDA's Priority Review Voucher
01:32pm, Tuesday, 22'nd Aug 2023
Krystal (KRYS) announces the sale of its priority review voucher for a consideration of $100 million. The stock of the company rises 5.2% on the news.
Krystal Biotech: Pioneering Rare Disease Gene Therapies
10:26pm, Monday, 31'st Jul 2023
Krystal Biotech's FDA-approved gene therapy for DEB sets a medical milestone, opening new revenue streams. With a robust financial health, Krystal prepares to launch a diverse pipeline of innovative g
Krystal Biotech, Inc. (KRYS) is on the Move, Here's Why the Trend Could be Sustainable
10:35am, Monday, 17'th Jul 2023
If you are looking for stocks that are well positioned to maintain their recent uptrend, Krystal Biotech, Inc. (KRYS) could be a great choice. It is one of the several stocks that passed through our "
Up 48% in 2023, Is This Biotech Stock a Buy?
08:30am, Saturday, 03'rd Jun 2023
Krystal Biotech recently reached an important milestone with the approval of its lead candidate Vyjuvek. Although this product represents a breakthrough, the overall market opportunity is not massive.
Krystal Clear: Krystal Biotech Clears Resistance in Good Volume
07:36am, Tuesday, 30'th May 2023
Last week, shares of the Pittsburgh-based genetic medicines developer surged more than 25% after the FDA approved its therapy for a rare skin disease called dystrophic epidermolysis bullosa, or DEB. A
Why Shares of Krystal Biotech Are Rising Monday
12:53pm, Monday, 22'nd May 2023
Krystal Biotech announced on Friday that Vyjuvek had been approved by the FDA to treat a rare skin disorder. The company said it plans to launch the gene therapy by the third quarter.
Krystal's (KRYS) Dermatology Drug Gets FDA Nod, Stock Up 10%
12:50pm, Monday, 22'nd May 2023
Krystal's (KRYS) stock soars 10% on Friday after the company announces the FDA approval of Vyjuvek for the treatment of patients six months of age or older with dystrophic epidermolysis bullosa.
Krystal Biotech stock rises after FDA approves treatment for rare skin disease
02:39pm, Friday, 19'th May 2023
Krystal Biotech Inc. KRYS, +5.49% shares rose Friday after the biotech drug company received Food and Drug Administration approval of a rare skin disease treatment. Krystal shares rose as much as 8% t
U.S. FDA approves Krystal Biotech's skin disorder gene therapy
02:05pm, Friday, 19'th May 2023
The U.S. Food and Drug Administration on Friday approved Krystal Biotech Inc's topical gene therapy for patients with a genetic skin disorder, making it the first-of-its kind treatment for epidermolys
Krystal Biotech: 2 Potential Regulatory Approvals To Carry It Forward
02:27pm, Monday, 08'th May 2023
Krystal Biotech, Inc. has a PDUFA date of May 19, 2023, established for the FDA to review B-VEC for potential U.S. marketing approval to treat patients with Dystrophic Epidermolysis Bullosa. There is
Krystal Biotech to Present at Association for Research in Vision and Ophthalmology Annual Meeting
07:00am, Thursday, 13'th Apr 2023
Clinical data on the compassionate use of B-VEC to treat a RDEB patient, with recurrent cicatrizing conjunctivitis that leads to conjunctival scarring, at the Bascom Palmer Eye Institute
Krystal Biotech: Reached My Price Target, Waiting For A Drop
05:20pm, Friday, 20'th Jan 2023
I sold out of Krystal Biotech stock after it hit my 65% profit price target. I am looking for another opportunity to enter.
The 7 Hottest Biotech Stocks to Own in 2023 and Beyond
06:21pm, Sunday, 18'th Dec 2022
Some of the hottest biotech stocks are safe and recession-proof. After all, we can't stop people from aging – at least, not yet.
Krystal Biotech to Present at 5th Annual Evercore ISI HealthCONx Conference
07:00am, Wednesday, 23'rd Nov 2022
PITTSBURGH, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) a biotechnology company focused on developing and commercializing genetic medicines for patients
